Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing (PEAX)
PEAX: Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing
Sponsor: Duke University
Listed as NCT02353715, this observational or N/A phase trial focuses on Prostate Cancer and remains completed. Sponsored by Duke University, it has been updated 13 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Jan 2026 — Present [monthly]
Completed
-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Mar 2020 — Jan 2021 [monthly]
Completed
▶ Show 8 earlier versions
-
Mar 2019 — Mar 2020 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Oct 2018 — Mar 2019 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Oct 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Oct 2017 — Apr 2018 [monthly]
Recruiting NA
-
Mar 2017 — Oct 2017 [monthly]
Recruiting NA
Phase: EARLY_PHASE1 → NA
-
Feb 2017 — Mar 2017 [monthly]
Recruiting EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting Phase 0
First recorded
Jul 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Duke University
For direct contact, visit the study record on ClinicalTrials.gov .